Literature DB >> 7534285

The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl.

J G Drachman1, J D Griffin, K Kaushansky.   

Abstract

c-Mpl is a member of the cytokine receptor superfamily, expressed primarily on hematopoietic cells. Recently, the c-Mpl ligand was cloned and found to have thrombopoietic activity. In this paper we report that ligand binding induced tyrosine phosphorylation in BaF3 cells engineered to express the murine Mpl receptor (BaF3/mMpl). Phosphorylation occurred within 1 min at cytokine concentrations sufficient for proliferation of receptor-bearing cells. Using specific antibodies for immunoprecipitation and Western blotting, several of these phosphorylated proteins were identified. Shc and Jak2, known cytokine signaling molecules, and the c-Mpl receptor were shown to be major substrates for tyrosine phosphorylation. In contrast, phospholipase C-gamma and phosphatidylinositol 3-kinase displayed little and no tyrosine phosphorylation, respectively, after thrombopoietin stimulation. Co-immunoprecipitation studies demonstrated that Jak2 became physically associated with c-Mpl relatively late in the observed time course (20-60 min), significantly later than tyrosine phosphorylation of Jak2 (1-5 min). These results suggest that c-Mpl induces signal transduction pathways similar to those of other known cytokines. Additionally, in light of its late physical association with c-Mpl following ligand binding, Jak2 may not be the initiating tyrosine kinase in the thrombopoietin-induced signaling cascade.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534285     DOI: 10.1074/jbc.270.10.4979

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway.

Authors:  M C Rouyez; C Boucheron; S Gisselbrecht; I Dusanter-Fourt; F Porteu
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Fine-tuning of hematopoietic stem cell homeostasis: novel role for ubiquitin ligase.

Authors:  Tomomasa Yokomizo; Elaine Dzierzak
Journal:  Genes Dev       Date:  2008-04-15       Impact factor: 11.361

3.  Orientation-specific signalling by thrombopoietin receptor dimers.

Authors:  Judith Staerk; Jean-Philippe Defour; Christian Pecquet; Emilie Leroy; Hélène Antoine-Poirel; Ian Brett; Miki Itaya; Steven O Smith; William Vainchenker; Stefan N Constantinescu
Journal:  EMBO J       Date:  2011-09-02       Impact factor: 11.598

4.  A proliferation switch for genetically modified cells.

Authors:  C A Blau; K R Peterson; J G Drachman; D M Spencer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

5.  JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.

Authors:  Rodolphe Besancenot; Damien Roos-Weil; Carole Tonetti; Hadjer Abdelouahab; Catherine Lacout; Florence Pasquier; Christophe Willekens; Philippe Rameau; Yann Lecluse; Jean-Baptiste Micol; Stefan N Constantinescu; William Vainchenker; Eric Solary; Stéphane Giraudier
Journal:  Blood       Date:  2014-08-20       Impact factor: 22.113

Review 6.  Thrombopoietin in normal and neoplastic stem cell development.

Authors:  Kenneth Kaushansky; Helen M Ranney
Journal:  Best Pract Res Clin Haematol       Date:  2009-12       Impact factor: 3.020

7.  Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation.

Authors:  B Rodríguez-Liñares; S P Watson
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

8.  An ENU-induced recessive mutation in Mpl leads to thrombocytopenia with overdominance.

Authors:  E Ricky Chan; Heather Lavender; Geqiang Li; Peter Haviernik; Kevin D Bunting; Mark D Adams
Journal:  Exp Hematol       Date:  2008-12-06       Impact factor: 3.084

9.  Critical role for ERK1/2 in bone marrow and fetal liver-derived primary megakaryocyte differentiation, motility, and proplatelet formation.

Authors:  Alexandra Mazharian; Steve P Watson; Sonia Séverin
Journal:  Exp Hematol       Date:  2009-07-18       Impact factor: 3.084

10.  New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.

Authors:  Ara Metjian; Charles S Abrams
Journal:  Biologics       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.